公开(公告)号：EP2504343A1

公开(公告)日：2012-10-03

申请号：EP10832452.6

申请日：2010-11-18

申请人： Boehringer Ingelheim International GmbH

发明人： LLINAS-BRUNET, Montse ,  BORDELEAU , Josée ,  GODBOUT, Cédrickx ,  LEBLANC, Melissa ,  MOREAU, Benoit ,  O'MEARA, Jeffrey

IPC分类号： C07D487/04 ,  A61K31/4709 ,  A61P31/14

CPC分类号： C07D487/04 ,  A61K31/4709

摘要： Compounds of the invention, which are macrocyclic peptide analogs containing an acylsulfonamide moiety, maintain good activity against NS3 proteases containing clinically relevant resistance mutations for this class as represented by genotype 1 a R155K, genotype 1 b D168V and genotype 1 a D168V resistance mutations. The compounds of the invention are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.